Intravenous Drug Use and AIDS

  • Don C. Des Jarlais
  • Samuel R. Friedman
  • Joycelyn Sue Woods

Abstract

Intravenous (IV) drug users have been the second largest group of persons to have developed acquired immune deficiency syndrome (AIDS) in the United States and in Western Europe. 10,627 (18%) of the 59,287 adult cases reported in the United States have occurred in heterosexual IV drug users, and another 4325 (7%) in IV drug users who also had male homosexuality as a risk factor.1 In Europe, 1944 (19.5%) of the 9930 adult cases have occurred in heterosexual IV drug users, and another 259 (3%) in IV drug users who also had male homosexual activity as a risk factor.2

Keywords

Drug User Acquire Immune Deficiency Syndrome Intravenous Drug User Injection Equipment Intravenous Drug Abuser 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Morbidity & Mortality Weekly Report 36, 15:35–15S, Atlanta, Center for Disease Control, 1987.Google Scholar
  2. 2.
    AIDS Surveillance in Europe, Quarterly Report No 16. Paris, World Health Organization Collaborating Centre on AIDS, 1987.Google Scholar
  3. 3.
    Musto D: The American Disease. New Haven, Yale University Press, 1973.Google Scholar
  4. 4.
    Courtwright DT: Dark Paradise: Opiate addiction in America before 1940. Cambridge, Harvard University Press, 1982.Google Scholar
  5. 5.
    Kolb L: Drug Addiction. Springfield, Illinois, Charles C Thomas, 1962.Google Scholar
  6. 6.
    Spitzer RL et al: DSM III Case Book: A Learning Companion to the Diagnostic and Statistical Manual of Mental Disorders, ed 3. New York, American Psychiatric Association, 1981.Google Scholar
  7. 7.
    Dole VP, Nyswander ME: A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193: 146150, 1965.Google Scholar
  8. 8.
    Agar HM: Ripping and Running: A Formal Ethnography of Urban Heroin Addicts. New York, Seminar Press, 1973.Google Scholar
  9. 9.
    Cohen HW, Marmor M, Des Jarlais DC, et al: Behavioral risk factors for HTLV-III/LAV seropositivity among intravenous drug abusers, in The International Conference on Acquired Immunodeficiency Syndrome (AIDS), Atlanta, April 14–17, 1985.Google Scholar
  10. 10.
    Weiss SH, Ginzberg HM, Saxinger WC, et al: Emerging high rates of human T-cell lymphotropic virus type I (HTLV-I) and HIV infection among U.S. drug abusers (DA), in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  11. 11.
    Angarano G, Pastore G, Monno L, et al: Rapid spread of HTLV-III infection among drug addicts in Italy. Lancet 2: 1302, 1985.PubMedCrossRefGoogle Scholar
  12. 12.
    Robertson JR, Bucknall ABV, Welsby PD, et al: Epidemic of AIDS related virus (HLTV-III/LAV) infection among intravenous drug users. Br Med J 292: 527–529, 1986.CrossRefGoogle Scholar
  13. 13.
    Schupbach J, Haller O Vogt M, et al: Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med 312: 265–270, 1985.PubMedCrossRefGoogle Scholar
  14. 14.
    Hunsmann G, Schneider J, Bayer H, et al: Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany. Klin Wochenschr 63: 233–235, 1985.PubMedCrossRefGoogle Scholar
  15. 15.
    Chaisson RE, Moss AR, Onishi R, et al: Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health 77: 169–172, 1987.PubMedCrossRefGoogle Scholar
  16. 16.
    Novick DM, Kreek MJ, Des Jarlais DC: Abstract of clinical research findings: therapeutic and historical aspects, in Harris LJ (ed): Problems of Drug Dependence 1985, Research monograph series 67. Rockville, Maryland, National Institute on Drug Abuse, 1986, pp 328–320.Google Scholar
  17. 17.
    Verani P: Seroprevalence among intravenous drug abusers in Italy, in Workshop on Epidemological Surveys on AIDS: Epidemiology of HIV Infection in Europe Spread among Intravenous Drug Users and the Heterosexual Population, Berlin, November 12–14, 1986.Google Scholar
  18. 18.
    Rex W: Increase of HIV seroprevalence among IVDA in West Berlin prisons since 1982, in Workshop on Epidemiological Surveys on AIDS: Epidemiology of HIV Infections in Europe Spread among Intravenous Drug Users and the Heterosexual Population, Berlin, November 12–14, 1986.Google Scholar
  19. 19.
    Worm AM: Incidence of HIV antibodies in IV drug abusers and prostitutes in Copenhagen, in Workshop on Epidemiological Surveys on AIDS: Epidemiology of HIV Infection in Europe Spread among Intravenous Drug Users and the Heterosexual Population, Berlin, November 12–14, 1986.Google Scholar
  20. 20.
    Des Jarlais DC, Friedman SR, Novick D, et al: HIV-1 infection among intravenous drug users in Manhattan, JAMA 261: 1008–1012, 1989.PubMedCrossRefGoogle Scholar
  21. 21.
    Weiss SH, Ginzburg HM, Goedert JJ, et al: Risk for HTLV-III exposure and AIDS among parenteral drug abusers in New Jersey, in The International Conference on the AIDS, Atlanta, April 14–17, 1985.Google Scholar
  22. 22.
    Schoenbaum EE, Selwyn PA, Klein RS, et al: Prevalence of and risk factors associated with HTLV-III/LAV antibodies among intravenous drug abusers in methadone programs in New York City, in The Second International Conference on AIDS, Paris, June 23–25, 1986.Google Scholar
  23. 23.
    Des Jarlais DC, Friedman SR, Strug D: AIDS among intravenous drug users: A socio-cultural perspective, in Feldman D, Johnson T (eds): The Social Dimensions of AIDS:Methods and Theory. New York, Praeger, 1986, pp 111–125.Google Scholar
  24. 24.
    Marmor M, Des Jarlais DC, Cohen H, et al: Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS 1: 39–44, 1987.PubMedGoogle Scholar
  25. 25.
    Darrow M: Risk factors among prostitutes, in Workshop on Epidemiological Surveys on AIDS: Epidemiology of HIV Infection in Europe Spread among Intravenous Drug Users and the Heterosexual Population, Berlin, November 12–14, 1986.Google Scholar
  26. 26.
    Des Jarlais DC Friedman SR: Ethnic Differences in HIV Seroprevalence Rates among Intravenous Drug Users. Rockville, Maryland, National Institute of Drug Abuse, in press.Google Scholar
  27. 27.
    D’Aquila RT, Williams AB, Peterson LR, et al: HIV seroprevalence among Connecticut intravenous drug users in 1986–87: Race/ethnicity as a risk factor for HIV seropositivity, in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  28. 28.
    Lange WR, Primm BJ., Tennant FS, et al: The geographic distribution of human immunodeficiency virus (HIV) antibodies in parenteral drug abusers, in The Third International Conference on AIDS. Washington, June 1–5, 1987.Google Scholar
  29. 29.
    van den Hoek JAR, Coutinho, RA, van Zadelhoff AW, et al: Prevalence, incidence and risk factors of HIV infection among drug users in Amsterdam, in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  30. 30.
    Des Jarlais DC, Marmor M, Thomas P: Kaposi’s sarcoma among four different risk groups. (Letter.) N Engl J Med 310: 1119, 1984.PubMedGoogle Scholar
  31. 31.
    Haverkos HW, Pinsky PF. Drotman DP, et al: Disease manifestations among homosexual men with acquired immunodeficiency syndrome: A possible role of nitrites in Kaposi’s sarcoma. Sex Transm Dis 12:203–208, 1985.Google Scholar
  32. 32.
    Drew WL, Mills J, Levy J: Cytomegalovirus infection and abnormal T-lymphocyte subset ratios in homosexual men. Ann Intern Med 103: 61–63, 1985.PubMedCrossRefGoogle Scholar
  33. 33.
    Des Jarlais DC, Stoneburner R, Thomas P: Declines in proportion of Kaposi’s sarcoma among cases of AIDS in multiple risk groups in New York City. (Letter.) Lancet ii: 1024–1025. 1987.Google Scholar
  34. 34.
    Goedert JJ, Biggar RJ, Weiss SH, et al: Three year incidence of AIDS among HTLV-III infected risk group members: A comparison of five cohorts. Science 231: 992–995, 1985.CrossRefGoogle Scholar
  35. 35.
    Des Jarlais DC, Friedman SR, Marmor M, et al: Development of AIDS, HIV seroconversion, and co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS 1: 105–111, 1987.PubMedGoogle Scholar
  36. 36.
    Selwyn PA, Schoenbaum EE, Hartel D: Natural history of HIV infection in intravenous drug abusers (IVDAs), in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  37. 37.
    Zagury D, Bernard J, Leonard R, et al: Long-term cultures of HTLV-III-infected T-cells: A model of cytopathology of T-cell depletion in AIDS. Science 231: 850–853, 1986.PubMedCrossRefGoogle Scholar
  38. 38.
    Des Jarlais DC, Friedman SR, Casriel C, et al: AIDS and preventing initiation into intravenous (IV) drug use. Psychol Health 1: 179–194, 1987.CrossRefGoogle Scholar
  39. 39.
    Des Jarlais DC, Friedman SR, Stonebumer RL: HIV infection and intravenous drug use: critical issues in transmission dynamics, infection outcomes, and prevention. Rev Infect Dis 10: 151–158, 1988.PubMedCrossRefGoogle Scholar
  40. 40.
    Stoneburner RL, Des Jarlais DC, Benezra D, et al: A larger spectrum of severe HIV- l -related disease in intravenous drug users in New York City. Science 242: 916–919, 1988.PubMedCrossRefGoogle Scholar
  41. 41.
    Friedman SR, Des Jarlais DC, Sotheran JL: AIDS and self-organization among intravenous drug users. Int J Addict 22: 201–220, 1987.PubMedGoogle Scholar
  42. 42.
    Des Jarlais DC, Friedman SR, Hopkins W: Risk reduction for AIDS among intravenous drug users. Ann Intern Med 103: 755–759, 1985.PubMedCrossRefGoogle Scholar
  43. 43.
    Des Jarlais DC, Hopkins W: “Free needles” for intravenous drug users at risk for AIDS: Current developments in New York City. (Letter.) N Engl J Med 313: 1476, 1985.PubMedGoogle Scholar
  44. 44.
    Friedman SR, Des Jarlais DC Sotheran JL: AIDS health education for intravenous drug users. J Health Educ Q 13: 383–393, 1986.CrossRefGoogle Scholar
  45. 45.
    McAuliffe WE, Doering S, Breer, P, et al: An evaluation of using ex-addict outreach workers to educate intravenous drug users about AIDS prevention, in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  46. 46.
    Jackson J, Rotkiewicz L: A Coupon Program: AIDS Education and Drug Treatment, in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  47. 47.
    Simpson DD, Savage JL, Sells SB: Data Book on Drug Treatment Outcomes: Follow-up Study of 19691972 Admissions to the Drug Abuse Reporting Program (DARP), report 78–10. Fort Worth, Institute of Behavior Research, Texas Christian University, 1978.Google Scholar
  48. 48.
    Abdul-Quader AS, Friedman SR, Des Jarlais DC, et al: Methadone maintenance and behavior by intravenous drug users that can transmit HIV. Contemp Drug Probl 14: 425–434, 1987.Google Scholar
  49. 49.
    Hanel D, Selwyn PA, Schoenbaum EE, et al: Methadone maintenance treatment (MMTP) and reduced risk of AIDS and AIDS-specific mortality in intravenous drug users (IVDUs), in The Fourth International Conference on AIDS, Stockholm, June 12–16, 1988.Google Scholar
  50. 50.
    Blix O, Gronbladh L: AIDS and IV heroin addicts: The preventive effect of methadone maintenance in Sweden, in The Fourth International Conference on AIDS, Stockholm, June 12–16, 1988.Google Scholar
  51. 51.
    Goldberg D, Watson H, Stuart F, et al: Pharmacy supply of needles and syringes-The effect on spread of HIV intravenous drug misusers, in The Fourth International Conference on AIDS, Stockholm, June 12–16, 1988.Google Scholar
  52. 52.
    Espinoza P, Bouchard I, Ballian P, et al: Has the open sale of syringes modified the syringe exchanging habits of drug addicts, in The Fourth International Conference on AIDS, Stockholm, June 12–16, 1988.Google Scholar
  53. 53.
    Fuchs D, Unterweger B, Hinterhuber H, et al: Successful preventive measures in a community of IV drug addicts, in The Fourth International Conference on AIDS, Stockholm, June 12–16, 1988.Google Scholar
  54. 54.
    Buning EC, van Brussel GHA, van Santen G: Amsterdam’s drug policy and its implications for controlling needle sharing, in Battjes R, Pickins R (eds): Needle Sharing among Intravenous Drug Abusers: National and International Perspectives. Research Monograph Series 80. Rockville, Maryland, National hnstitute of Drug Abuse, 1988, pp 59–74.Google Scholar
  55. 55.
    Alldritt L, Dolan K, Donoghoe M, et al: HIV and the injecting drug user: clients of syringe exchange schemes in England and Scotland, in The Fourth International Conference on AIDS, Stockholm, June 1216, 1988.Google Scholar
  56. 56.
    Watters JK: Preventing human immunodeficiency virus contagion among intravenous drug users: The impact of street-based education on risk-behavior, in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  57. 57.
    Watters JK, Case P, Huang, K, et al: HIV seroepidemiology and behavior change in intravenous drug users: Progress report on the effectiveness of street-based prevention, in The Fourth International Conference on AIDS, Stockholm, June 12–16, 1988.Google Scholar
  58. 58.
    Coates T: Change in sexual behavior among gay and bisexual men since the beginning of the AIDS epidemic. United States Congress, Office of Technology Assessment, in press.Google Scholar
  59. 59.
    Friedman SR, Des Jarlais DC, Goldsmith D: An overview of current AIDS prevention efforts aimed at intravenous drug users. J Drug Issues 19: 93–112, 1989.Google Scholar
  60. 60.
    Casadonte P, Des Jarlais DC, Smith T, et al: Psychological and behavioral impact of learning HTLV-III/LAV antibody test results, in The Second International Conference on Acquired Immunodeficiency Syndrome, Paris, June 23–25, 1986.Google Scholar
  61. 61.
    Cox CP, Selwyn PA, Schoenbaum EE, et al: Psychological and behavioral consequences of HTLV-III/LAV antibody testing and notification among intravenous drug abusers in a methadone program in New York City, in The Second International Conference on AIDS, Paris, June 23–25, 1986.Google Scholar
  62. 62.
    Marlink RG, Foss B, Swift R, et al: High rate of HTLV-III/LAV exposure in IVDA’s from a small-sized city and the failure of specialized methadone maintenance to prevent further drug use, in The Third International Conference on AIDS, Washington, June 1–5, 1987.Google Scholar
  63. 63.
    Des Jarlais DC, Friedman SR, Goldsmith D, et al: Heterosexual transmission of HIV from intravenous drug users: Regular partnerships and prostitution, in Voeller B, Gottlieb M, Reinisch J (eds): AIDS and Sex: An Integrated Biomedical and Biobehavior Approach. New York, Oxford University Press, in press.Google Scholar
  64. 64.
    Des Jarlais DC, Friedman SR: HIV infection among persons who inject illicit drugs: problems and prospects. J AIDS 1: 267–273, 1988.Google Scholar
  65. 65.
    Winkelstein W, Samuel M, Padian N, et al: The San Francisco men’s health study. III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1983–86. Am J Public Health 77: 685–689, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Don C. Des Jarlais
    • 1
    • 2
  • Samuel R. Friedman
    • 2
  • Joycelyn Sue Woods
    • 2
  1. 1.Beth Israel Medical CenterNew YorkUSA
  2. 2.Narcotic and Drug Research, Inc.New YorkUSA

Personalised recommendations